Saniona specializes in the discovery and development of ion channel modulators, utilizing a proprietary drug discovery engine that has generated over 20,000 unique molecules. The company focuses on addressing neurological disorders, including epilepsy and hypothalamic obesity, by advancing multiple candidates through clinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
Neurological disorders like epilepsy and hypothalamic obesity affect millions worldwide, often requiring novel therapeutic interventions. Traditional drug discovery methods can be inefficient in identifying and developing effective treatments for these complex conditions.
Solution
Saniona is a biopharmaceutical company specializing in the discovery and development of ion channel modulators to address neurological disorders. The company utilizes a proprietary drug discovery engine to design and generate novel molecules that target specific ion channels involved in disease pathology. Saniona is advancing a pipeline of drug candidates through clinical trials, focusing on indications with significant unmet medical needs, such as epilepsy and hypothalamic obesity. Their approach aims to develop highly specific and effective treatments by leveraging their expertise in ion channel biology and drug discovery.
Target Audience
The primary target audience includes patients suffering from neurological disorders such as epilepsy and hypothalamic obesity, as well as their caregivers and healthcare providers.
Features
- Proprietary drug discovery engine for generating novel ion channel modulators.
- Library of over 20,000 unique molecules targeting various ion channels.
- Pipeline of drug candidates in clinical development for neurological disorders.
- Focus on epilepsy, hypothalamic obesity, and other rare diseases.
- Expertise in ion channel biology and pharmacology.